| For: |
Liu J, Fu XQ, Zhou W, Yu HG, Yu JP, Luo HS. LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i2/181.htm |
| Number | Citing Articles |
| 1 |
Jennifer W. Harris, Tianyan Gao, B. Mark Evers. Intestinal Tumorigenesis. 2015; doi: 10.1007/978-3-319-19986-3_4
|
| 2 |
Qianhui Sun, Jingyuan Wu, Guanghui Zhu, Tingting Li, Xiaoyu Zhu, Baoyi Ni, Bowen Xu, Xinyi Ma, Jie Li. Lactate-related metabolic reprogramming and immune regulation in colorectal cancer. Frontiers in Endocrinology 2023; 13 doi: 10.3389/fendo.2022.1089918
|
| 3 |
Ahmad R. Safa, Karen E. Pollok. Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy. Cancers 2011; 3(2) doi: 10.3390/cancers3021639
|
| 4 |
Zhen Lu, Aman Xu, Xiao Yuan, Kaiwei Chen, Likun Wang, Tao Guo. Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3‑kinase/protein kinase�B/glycogen synthase kinase 3β signaling pathway. Oncology Letters 2018; doi: 10.3892/ol.2018.8979
|
| 5 |
CHENFEI ZHOU, JUN JI, MIN SHI, LIU YANG, YINGYAN YU, BINGYA LIU, ZHENGGANG ZHU, JUN ZHANG. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin-induced Src activation in gastric cancer cells. Molecular Medicine Reports 2014; 10(5) doi: 10.3892/mmr.2014.2548
|
| 6 |
Leimarembi Devi Naorem, Mathavan Muthaiyan, Ishita Bhattacharyya, Dinakara Rao Ampasala, Amouda Venkatesan. A Theranostic and Precision Medicine Approach for Female-Specific Cancers. 2021; doi: 10.1016/B978-0-12-822009-2.00002-9
|
| 7 |
Jingjing Yue, Jie Ma, Yangyang Li, Hongbo Dong, Yongge He, Minhua Chen, Fang Fang, Weihua Xiao. Enhanced efficacy of gastric cancer treatment by a combination of NK cells and chemotherapy. iScience 2026; 29(6) doi: 10.1016/j.isci.2026.115915
|
| 8 |
Olga Kersy, Shelly Loewenstein, Nir Lubezky, Osnat Sher, Natalie B. Simon, Joseph M. Klausner, Guy Lahat. Omental Tissue-Mediated Tumorigenesis of Gastric Cancer Peritoneal Metastases. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.01267
|
| 9 |
Guoqiong Lei, Sushun Liu, Xin Yang, Chao He, Ravindran Caspa Gokulan. TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell. Canadian Journal of Gastroenterology and Hepatology 2021; 2021(1) doi: 10.1155/2021/8870907
|
| 10 |
Giuseppe Siragusa, Laura Tomasello, Carla Giordano, Giuseppe Pizzolanti. Survivin (BIRC5): Implications in cancer therapy. Life Sciences 2024; 350 doi: 10.1016/j.lfs.2024.122788
|
| 11 |
Hui-Hui Hu, Hai-Li Shang, Yongjing Ren, Hui-Fang Lv, Shuiping Tu, Jian-Zheng Wang, Ya-Nan Gong, Zhi-Fei Li, He Zhang, Tiepeng Li, Yuhang Wang, Bei-Bei Chen, Sai-Qi Wang, Xiao-Bing Chen. Resibufogenin and Oxaliplatin Synergistically Inhibit Diffuse Gastric Cancer by Inactivating the FAK/AKT/GSK3β/β-Catenin Signaling Pathway. Recent Patents on Anti-Cancer Drug Discovery 2026; 21(1) doi: 10.2174/0115748928320605241112094549
|
| 12 |
Duncan Ayers, Alessandro Nasti. Utilisation of Nanoparticle Technology in Cancer Chemoresistance. Journal of Drug Delivery 2012; 2012 doi: 10.1155/2012/265691
|
| 13 |
Guiqin Hou, Qi Zhao, Mengying Zhang, Tianli Fan, Mingyue Liu, Xiaojing Shi, Yandan Ren, Yang Wang, Jiaxu Zhou, Zhaoming Lu. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma. Biomedicine & Pharmacotherapy 2018; 106 doi: 10.1016/j.biopha.2018.07.075
|
| 14 |
Hui Zhang, Yidan Lin, Minxue Zhuang, Lin Zhu, Yongmei Dai, Mengbo Lin. Screening and identification of CNIH4 gene associated with cell proliferation in gastric cancer based on a large-scale CRISPR-Cas9 screening database DepMap. Gene 2023; 850 doi: 10.1016/j.gene.2022.146961
|
| 15 |
Feng Qiu, Chun‐hua Shi, Jun Zheng, Yu‐bin Liu. Periostin Mediates the Increased Pro‐Angiogenic Activity of Gastric Cancer Cells under Hypoxic Conditions. Journal of Biochemical and Molecular Toxicology 2013; 27(7) doi: 10.1002/jbt.21498
|
| 16 |
Fusao Sumiyama, Hoang Hai Duong, Hideyuki Matsushima, Kosuke Matsui, Terufumi Yoshida, Hidekazu Yamamoto, Hisashi Kosaka, Mitsugu Sekimoto, Van Khanh Nguyen, Thanh Tung Lai, Takuya Ohigashi, Tomoya O. Akama, Kengo Yoshii, Emiho Oe, Nanami Fujisawa, Mitsuhiro Ebara, Masaki Kaibori. Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models. Nanomaterials 2025; 15(19) doi: 10.3390/nano15191524
|
| 17 |
R. Reilly, M. S. Mroz, E. Dempsey, K. Wynne, S. J. Keely, E. F. McKone, C. Hiebel, C. Behl, J. A. Coppinger. Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-06588-z
|
| 18 |
Yue Song, Zhao-xia Li, Xi Liu, Rui Wang, Li-wei Li, Qingyu Zhang. The Wnt/β-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation. Tumor Biology 2017; 39(7) doi: 10.1177/1010428317712617
|
| 19 |
Yi-Jun Wang, Xiao-Li Xie, Hong-Qun Liu, Hui Tian, Xiao-Yu Jiang, Jiu-Na Zhang, Hui-Qing Jiang, Shi-Mao Liu, Xiao-Xu Jin, Xue Zhou, Shu-Ling Wang, Ting Liu, Sheng-Xiong Chen. Prostaglandin F<sub>2α</sub> synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F<sub>2α</sub>-dependent and F<sub>2α</sub>-independent mechanism. World Journal of Gastroenterology 2023; 29(39): 5452-5470 doi: 10.3748/wjg.v29.i39.5452
Abstract(893) |
Core Tip(936) |
Full Article(HTML)(3087)
|
Full Article (PDF)-29404K(259)
|
Full Article with Cover (PDF)-30122K(242)
|
Full Article (Word)-8578K(44)
|
Full Article (XML)-147K(193)
|
Audio-9262K(21)
|
Peer-Review Report-234K(157)
|
Answering Reviewers-832K(161)
|
Supplementary Material-830K(169)
|
Times Cited (7)
|
Total Visits (5162)
|
Open
|